Novo Nordisk reports additional CagriSema weight-loss findings
FluxFactory/E+ via Getty Images
Novo Nordisk (NVO) said two additional analyses of its late-stage REDEFINE 1 trial found differing weight-loss patterns and improvements in daily functioning among adults receiving its experimental obesity treatment CagriSema.
For investors, the findings add evidence that could help Novo position
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.